Clinical Trial Search

Primary: Change in Mean Trough Levels of 17-OHPC in the Three Groups at 20-22 Weeks, 27-29 Weeks and 34-36 Weeks. — 10.1; 13.0; 18.0; 11.5 ng/ml

Primary: Number of Participants Who Achieve at Least a 50% Reduction in Their Primary Problematic Symptom (Either Pain or Tingling) From Baseline on Day 14 — 10; 5 Participants…

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.59; -2.59; -0.93 Percentage of HbA1c — p=<0.001

Primary: Percentage of Participants With Overall Response — 25.0; 17.1; 23.4; 17.8 Percentage of Participants — p=0.152

Primary: Event-free Survival — 7 Participants

Primary: Cmax of Plasma DF 2156Y — 67.345; 95.982 μg/mL — p=<0.0001

Primary: Probability of Resolution of Nonadherence Within 30 Days — .4286; .4290; .4554; .4437 Proportion of resolved NAEs within 30 — p=<0.01

Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants

Primary: Parts 1 and 2: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 0; 0; 0; 0 percentage of participants

Primary: Number of Participants With Completely Healed Lower Extremity Wounds — 20; 18 Participants

Primary: Primary Safety Endpoint: Composite Endpoint Rate of Procedure-related Complications, or All-cause Death or Major Bleeding (Defined as Type 3 or Greater Based on the…

Primary: Time Required to Achieve Hemostasis — 0; 15 minutes

Primary: Time to First Rescue Treatment — 5; 4; NA months

Primary: The Number of Participants With Technical Placement Success and With 12-month Freedom From New Symptomatic Pulmonary Embolism (PE) While a Filter is Indwelling. — 317…

Primary: Cohort 1: Number of Participants Who Achieved Sitting Alone for at Least 30 Seconds — 14 Participants